chr2-47476436-G-T
Variant summary
Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PM2_SupportingPS3PP4_StrongPP3_Moderate
This summary comes from the ClinGen Evidence Repository: The NM_000251.3(MSH2):c.2075G>T (p.Gly692Val) variant is a missense variant and leads to a change of Glycin to Valin at position 692. This variant has been reported in at least 3 independent CRC/Endometrial MSI-H tumours in ≥2 families using a standard panel of 5-10 markers and/or loss of MMR protein expression consistent with the variant location (PMID:29212164, PMID:21879275; ClinVar submission: VCV000090880.2) (PP4_STR met)Furthermore, the variant has been detected in a 9y old patient with CMMR-D in combination with a other pathogenic variant in MSH2/EPCAM. (PM3 met)The CIMRA functional odds is 150.82, which exceeds the threshold of 18.7 (PS3 met). The prior probability is 93.9 which exceeds the threshold of 18.7 (PP3_MOD met). The variant is not reported in gnomAD v4.1 (PM2_supporting met). In summary, this variant meets the criteria to be classified as pathogenic based on the ACMG/AMP criteria applied, as specified by the ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis: criteria PS3, PP3_MOD, PP4_STR, PM3 and PM2_supporting applied. (VCEP specifications version 1) LINK:https://erepo.genome.network/evrepo/ui/classification/CA019969/MONDO:0007356/137
Frequency
Consequence
NM_000251.3 missense
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, G2P
- Lynch syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Ambry Genetics, Labcorp Genetics (formerly Invitae)
- Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- mismatch repair cancer syndrome 2Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae)
- ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- prostate cancerInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 11 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000251.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MSH2 | MANE Select | c.2075G>T | p.Gly692Val | missense | Exon 13 of 16 | NP_000242.1 | P43246-1 | ||
| MSH2 | c.2075G>T | p.Gly692Val | missense | Exon 13 of 18 | NP_001393603.1 | ||||
| MSH2 | c.2075G>T | p.Gly692Val | missense | Exon 13 of 18 | NP_001393560.1 |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MSH2 | TSL:1 MANE Select | c.2075G>T | p.Gly692Val | missense | Exon 13 of 16 | ENSP00000233146.2 | P43246-1 | ||
| MSH2 | TSL:1 | c.2075G>T | p.Gly692Val | missense | Exon 13 of 16 | ENSP00000384199.1 | E9PHA6 | ||
| MSH2 | c.2126G>T | p.Gly709Val | missense | Exon 14 of 17 | ENSP00000588166.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at